Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Company Overview

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules.

Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.

Key Stats

• Today's Range: $6.86 to $7.18
• 50-Day Range: $6.86 to $8.71
• 52-Week Range: $6.10 to $28.67
• Volume: 274,446 shs
• Average Volume: 210,546 shs
• Market Capitalization: $481.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.22
• Consensus Rating: Moderate Buy

Bicycle Therapeutics Stock Analysis - MarketRank™

Bicycle Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 421st out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Bicycle Therapeutics has a consensus price target of $22.22, representing about 219.7% upside from its current price of $6.95.

Amount of Analyst Coverage

Bicycle Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicycle Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicycle Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicycle Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.98% of the float of Bicycle Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 3.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicycle Therapeutics does not currently pay a dividend.

Dividend Growth

Bicycle Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.98% of the float of Bicycle Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 3.64%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.64

News Sentiment

Bicycle Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,820.00 in company stock.

Percentage Held by Insiders

22.90% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCYC Stock Analysis - Frequently Asked Questions

How have BCYC shares performed this year?

Bicycle Therapeutics' stock was trading at $14.00 at the start of the year. Since then, BCYC shares have decreased by 50.4% and is now trading at $6.95.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) issued its quarterly earnings data on Friday, August, 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by $0.19. The firm earned $2.90 million during the quarter, compared to the consensus estimate of $9.43 million. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative trailing twelve-month return on equity of 32.43%.

When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Bicycle Therapeutics' major shareholders?

Top institutional investors of Bicycle Therapeutics include Armistice Capital LLC (4.04%), Westfield Capital Management Co. LP (4.02%), Candriam S.C.A. (1.69%) and Tybourne Capital Management HK Ltd. (1.44%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Alethia Young, Travis Alvin Thompson and Lee Kalowski.
View institutional ownership trends.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCYC
• CIK: 1761612
• Web: www.bicycletherapeutics.com
• Phone: 441223261503
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bicycle Therapeutics: $22.22
• High Price Target: $44.00
• Low Price Target: $10.00
• Potential Upside/Downside: +211.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.03 million
• Net Margins: -1,257.00%
• Pretax Margin: -1,287.33%
• Return on Equity: -32.43%
• Return on Assets: -26.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.39
• Quick Ratio: 10.39

Sales & Book Value

• Annual Sales: $19.28 million
• Price / Sales: 25.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.48 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 69,307,000
• Free Float: 63,416,000
• Market Cap: $494.16 million
• Optionable: Optionable
• Beta: 1.41